Cargando…

Coronavirus Antiviral Research Database (CoV-RDB): An Online Database Designed to Facilitate Comparisons between Candidate Anti-Coronavirus Compounds

Background: To prioritize the development of antiviral compounds, it is necessary to compare their relative preclinical activity and clinical efficacy. Methods: We reviewed in vitro, animal model, and clinical studies of candidate anti-coronavirus compounds and placed extracted data in an online rel...

Descripción completa

Detalles Bibliográficos
Autores principales: Tzou, Philip L., Tao, Kaiming, Nouhin, Janin, Rhee, Soo-Yon, Hu, Benjamin D., Pai, Shruti, Parkin, Neil, Shafer, Robert W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7551675/
https://www.ncbi.nlm.nih.gov/pubmed/32916958
http://dx.doi.org/10.3390/v12091006
_version_ 1783593234860081152
author Tzou, Philip L.
Tao, Kaiming
Nouhin, Janin
Rhee, Soo-Yon
Hu, Benjamin D.
Pai, Shruti
Parkin, Neil
Shafer, Robert W.
author_facet Tzou, Philip L.
Tao, Kaiming
Nouhin, Janin
Rhee, Soo-Yon
Hu, Benjamin D.
Pai, Shruti
Parkin, Neil
Shafer, Robert W.
author_sort Tzou, Philip L.
collection PubMed
description Background: To prioritize the development of antiviral compounds, it is necessary to compare their relative preclinical activity and clinical efficacy. Methods: We reviewed in vitro, animal model, and clinical studies of candidate anti-coronavirus compounds and placed extracted data in an online relational database. Results: As of August 2020, the Coronavirus Antiviral Research Database (CoV-RDB; covdb.stanford.edu) contained over 2800 cell culture, entry assay, and biochemical experiments, 259 animal model studies, and 73 clinical studies from over 400 published papers. SARS-CoV-2, SARS-CoV, and MERS-CoV account for 85% of the data. Approximately 75% of experiments involved compounds with known or likely mechanisms of action, including monoclonal antibodies and receptor binding inhibitors (21%), viral protease inhibitors (17%), miscellaneous host-acting inhibitors (10%), polymerase inhibitors (9%), interferons (7%), fusion inhibitors (5%), and host protease inhibitors (5%). Of 975 compounds with known or likely mechanism, 135 (14%) are licensed in the U.S. for other indications, 197 (20%) are licensed outside the U.S. or are in human trials, and 595 (61%) are pre-clinical investigational compounds. Conclusion: CoV-RDB facilitates comparisons between different candidate antiviral compounds, thereby helping scientists, clinical investigators, public health officials, and funding agencies prioritize the most promising compounds and repurposed drugs for further development.
format Online
Article
Text
id pubmed-7551675
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-75516752020-10-14 Coronavirus Antiviral Research Database (CoV-RDB): An Online Database Designed to Facilitate Comparisons between Candidate Anti-Coronavirus Compounds Tzou, Philip L. Tao, Kaiming Nouhin, Janin Rhee, Soo-Yon Hu, Benjamin D. Pai, Shruti Parkin, Neil Shafer, Robert W. Viruses Article Background: To prioritize the development of antiviral compounds, it is necessary to compare their relative preclinical activity and clinical efficacy. Methods: We reviewed in vitro, animal model, and clinical studies of candidate anti-coronavirus compounds and placed extracted data in an online relational database. Results: As of August 2020, the Coronavirus Antiviral Research Database (CoV-RDB; covdb.stanford.edu) contained over 2800 cell culture, entry assay, and biochemical experiments, 259 animal model studies, and 73 clinical studies from over 400 published papers. SARS-CoV-2, SARS-CoV, and MERS-CoV account for 85% of the data. Approximately 75% of experiments involved compounds with known or likely mechanisms of action, including monoclonal antibodies and receptor binding inhibitors (21%), viral protease inhibitors (17%), miscellaneous host-acting inhibitors (10%), polymerase inhibitors (9%), interferons (7%), fusion inhibitors (5%), and host protease inhibitors (5%). Of 975 compounds with known or likely mechanism, 135 (14%) are licensed in the U.S. for other indications, 197 (20%) are licensed outside the U.S. or are in human trials, and 595 (61%) are pre-clinical investigational compounds. Conclusion: CoV-RDB facilitates comparisons between different candidate antiviral compounds, thereby helping scientists, clinical investigators, public health officials, and funding agencies prioritize the most promising compounds and repurposed drugs for further development. MDPI 2020-09-09 /pmc/articles/PMC7551675/ /pubmed/32916958 http://dx.doi.org/10.3390/v12091006 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Tzou, Philip L.
Tao, Kaiming
Nouhin, Janin
Rhee, Soo-Yon
Hu, Benjamin D.
Pai, Shruti
Parkin, Neil
Shafer, Robert W.
Coronavirus Antiviral Research Database (CoV-RDB): An Online Database Designed to Facilitate Comparisons between Candidate Anti-Coronavirus Compounds
title Coronavirus Antiviral Research Database (CoV-RDB): An Online Database Designed to Facilitate Comparisons between Candidate Anti-Coronavirus Compounds
title_full Coronavirus Antiviral Research Database (CoV-RDB): An Online Database Designed to Facilitate Comparisons between Candidate Anti-Coronavirus Compounds
title_fullStr Coronavirus Antiviral Research Database (CoV-RDB): An Online Database Designed to Facilitate Comparisons between Candidate Anti-Coronavirus Compounds
title_full_unstemmed Coronavirus Antiviral Research Database (CoV-RDB): An Online Database Designed to Facilitate Comparisons between Candidate Anti-Coronavirus Compounds
title_short Coronavirus Antiviral Research Database (CoV-RDB): An Online Database Designed to Facilitate Comparisons between Candidate Anti-Coronavirus Compounds
title_sort coronavirus antiviral research database (cov-rdb): an online database designed to facilitate comparisons between candidate anti-coronavirus compounds
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7551675/
https://www.ncbi.nlm.nih.gov/pubmed/32916958
http://dx.doi.org/10.3390/v12091006
work_keys_str_mv AT tzouphilipl coronavirusantiviralresearchdatabasecovrdbanonlinedatabasedesignedtofacilitatecomparisonsbetweencandidateanticoronaviruscompounds
AT taokaiming coronavirusantiviralresearchdatabasecovrdbanonlinedatabasedesignedtofacilitatecomparisonsbetweencandidateanticoronaviruscompounds
AT nouhinjanin coronavirusantiviralresearchdatabasecovrdbanonlinedatabasedesignedtofacilitatecomparisonsbetweencandidateanticoronaviruscompounds
AT rheesooyon coronavirusantiviralresearchdatabasecovrdbanonlinedatabasedesignedtofacilitatecomparisonsbetweencandidateanticoronaviruscompounds
AT hubenjamind coronavirusantiviralresearchdatabasecovrdbanonlinedatabasedesignedtofacilitatecomparisonsbetweencandidateanticoronaviruscompounds
AT paishruti coronavirusantiviralresearchdatabasecovrdbanonlinedatabasedesignedtofacilitatecomparisonsbetweencandidateanticoronaviruscompounds
AT parkinneil coronavirusantiviralresearchdatabasecovrdbanonlinedatabasedesignedtofacilitatecomparisonsbetweencandidateanticoronaviruscompounds
AT shaferrobertw coronavirusantiviralresearchdatabasecovrdbanonlinedatabasedesignedtofacilitatecomparisonsbetweencandidateanticoronaviruscompounds